Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
COVID-19 pandemic is currently affecting the globe. To date, there is no effective oral
therapy against SARS-CoV2 infection. The investigators propose to test as a repurposing drug
combination, a short course of tenofovir disoproxil and emtricitabine (TDF/FTC), as a
proof-of-concept randomized open-label study to test its viral efficacy against SARS-CoV2.